ACDN 01
Alternative Names: ACDN-01Latest Information Update: 02 Jul 2024
At a glance
- Originator Ascidian Therapeutics
- Class Eye disorder therapies; Gene therapies; RNA
- Mechanism of Action ATP binding cassette transporter subfamily A member 4 expression modulators; RNA splicing modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Cone rod dystrophies; Stargardt disease
Most Recent Events
- 11 Jun 2024 Phase-I/II clinical trials in Cone-rod-dystrophies in USA (Subretinal) (NCT06467344)
- 11 Jun 2024 Phase-I/II clinical trials in Stargardt disease in USA (Subretinal) (NCT06467344)
- 29 Jan 2024 Ascidian Therapeutics plans a phase I/II STELLAR trial for Stargardt disease and Retinal disorders in USA in 1H of 2024